[go: up one dir, main page]

AR041021A1 - Composicion topica - Google Patents

Composicion topica

Info

Publication number
AR041021A1
AR041021A1 ARP030103005A ARP030103005A AR041021A1 AR 041021 A1 AR041021 A1 AR 041021A1 AR P030103005 A ARP030103005 A AR P030103005A AR P030103005 A ARP030103005 A AR P030103005A AR 041021 A1 AR041021 A1 AR 041021A1
Authority
AR
Argentina
Prior art keywords
weight
percent
group
composition
diclofenac
Prior art date
Application number
ARP030103005A
Other languages
English (en)
Original Assignee
Novartis Consumer Health Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31896841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR041021(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Consumer Health Sa filed Critical Novartis Consumer Health Sa
Publication of AR041021A1 publication Critical patent/AR041021A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones farmacéuticas tópicas que comprenden a la sal sódica de diclofenaco en cantidades inusualmente bajas. Estas composiciones representan geles en emulsión opacos, en donde se mantiene completamente disuelto el diclofenaco. Reivindicación 1: Una composición farmacéutica pretendida para uso tópico, cuya composición está en la forma de un gel en emulsión opaco, y cuya composición comprende: a) del 0.02 al 0.4 por ciento (peso / peso) de sal sódica de diclofenaco, b) cuando menos el 50 por ciento (peso / peso) de agua, c) del 0 al 30 por ciento (peso / peso) de cuando menos un alcanol C2-4, d) del 3 al 20 por ciento (peso / peso) de un solvente de glicol seleccionado a partir del grupo que consiste en propilenglicol y polietilenglicol (200-20.000), e) del 0.2 al 3 por ciento (peso / peso) de cuando menos un agente gelificante seleccionado a partir del grupo que consiste en carbómeros, f) del 2 al 8 por ciento (peso / peso) de cuando menos un lípido que forme la fase oleosa del gel en emulsión, g) del 1 al 5 por ciento (peso / peso) de cuando menos un tensoactivo no iónico, y h) un agente básico seleccionado a partir del grupo que consiste en amoniaco, hidróxido de sodio, e hidróxido de potasio, para ajustar de la composición total a 6.5-8; con la condición de que esta composición esté exenta de un fármaco antifúngico.
ARP030103005A 2002-08-22 2003-08-20 Composicion topica AR041021A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02018772 2002-08-22

Publications (1)

Publication Number Publication Date
AR041021A1 true AR041021A1 (es) 2005-04-27

Family

ID=31896841

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030103005A AR041021A1 (es) 2002-08-22 2003-08-20 Composicion topica

Country Status (16)

Country Link
US (3) US7732489B2 (es)
EP (1) EP1536836B1 (es)
AR (1) AR041021A1 (es)
AT (1) ATE390149T1 (es)
AU (1) AU2003264086B2 (es)
BR (1) BR0313701A (es)
CA (1) CA2496469C (es)
DE (1) DE60319997T2 (es)
DK (1) DK1536836T3 (es)
ES (1) ES2300645T3 (es)
MX (1) MXPA05002077A (es)
PE (1) PE20040321A1 (es)
PT (1) PT1536836E (es)
SI (1) SI1536836T1 (es)
TW (1) TWI316857B (es)
WO (1) WO2004017998A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1588697A1 (en) * 2004-04-16 2005-10-26 Kurt H. Prof. Dr. Bauer Emulsion gel for topical application of pharmaceuticals
FR2882552B1 (fr) * 2005-02-25 2008-12-26 Galderma Sa Gel aqueux de haute stabilite a base de metronidazole et procedes pour leur preparation
WO2006116661A2 (en) * 2005-04-27 2006-11-02 Avocet Polymer Technologies, Inc. Polyethylene glycol based composition for topical treatment of a closed wound with therapeutic pharmaceuticals
JP2010502764A (ja) * 2006-09-11 2010-01-28 バイオマス リミテッド テルル含有化合物の局所製剤
CN104606126A (zh) 2006-10-17 2015-05-13 纽沃研究股份有限公司 双氯芬酸凝胶
GB0704846D0 (en) * 2007-03-13 2007-04-18 Futura Medical Dev Ltd Topical pharmaceutical formulation
DE102007034976A1 (de) * 2007-07-26 2009-01-29 Bayer Healthcare Ag Arzneimittel zur transdermalen Anwendung bei Tieren
EP2055298A1 (en) 2007-10-30 2009-05-06 Novartis AG Topical composition
US20100099766A1 (en) * 2008-10-16 2010-04-22 Novartis Ag Topical NSAID compositions having sensate component
US20100100060A1 (en) * 2008-10-17 2010-04-22 Novartis Ag Applicator for pharmaceutical product and method of using same
DE102009008094A1 (de) * 2009-02-09 2010-08-19 Barnikol-Keuten, Doris, Dr. In situ Haft-Gelbildende Zubereitungen, insbesondere zur topischen Anwendung auf befeuchtete Haut/Schleimhaut
US8546450B1 (en) 2009-03-31 2013-10-01 Nuvo Research Inc. Treatment of pain with topical diclofenac compounds
US8618164B2 (en) 2009-03-31 2013-12-31 Nuvo Research Inc. Treatment of pain with topical diclofenac compounds
CA2757310A1 (en) 2009-04-08 2010-10-14 Cadila Healthcare Limited Stable pharmaceutical compositions of diclofenac
CA2784827C (en) * 2009-12-16 2018-10-23 Shasun Pharmaceuticals Limited Composition of dexibuprofen transdermal hydrogel
WO2013014680A1 (en) 2011-07-28 2013-01-31 Cadila Healthcare Limited Method for treatment of pain and inflammation
ITMI20121205A1 (it) 2012-07-11 2014-01-12 Glycores 2000 Srl Composizione con attivita' antinfiammatoria ed analgesica da somministrare per uso esterno mediante vaporizzazione
MX2015000541A (es) * 2012-07-12 2015-05-11 Ferring Bv Formulaciones de diclofenaco.
RU2702898C2 (ru) 2014-09-10 2019-10-14 Гск Консьюмер Хелткер С.А. Композиции диклофенака натрия для местного применения
GB201502845D0 (en) * 2015-02-20 2015-04-08 Futura Medical Dev Ltd Topical pharmaceutical formulation
JP6598619B2 (ja) * 2015-09-28 2019-10-30 株式会社ポーラファルマ 物性で特定される皮膚外用剤
FR3064495B1 (fr) 2017-03-31 2021-04-02 Total Marketing Services Composition a base d'uree pour le traitement des gaz d'echappement
EP4408393A1 (en) 2021-10-01 2024-08-07 Nutrition & Biosciences USA 1, LLC Hydrocolloid blend compositions for topical application
EP4499036A1 (en) 2022-03-25 2025-02-05 Glycores 2000 srl Topical pharmaceutical composition with anti-inflammatory and analgesic activity and uses thereof
US20250099369A1 (en) 2023-09-27 2025-03-27 Andros Pharmaceuticals Co., Ltd. Topical delivery compositions comprising non-steroidal anti-inflammatory drugs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH655656B (es) * 1982-10-07 1986-05-15
WO1992007561A1 (en) * 1990-10-30 1992-05-14 Ss Pharmaceutical Co., Ltd. Antiphlogistic and analgesic gel preparation
JPH06509099A (ja) * 1991-07-03 1994-10-13 サノ・コーポレーシヨン ジクロフエナツクの経皮デリバリーに対する組成物及び方法
US5399342A (en) * 1993-02-03 1995-03-21 Dow Corning Corporation Cosmetics with enhanced durability
CN1210463A (zh) * 1996-02-07 1999-03-10 株式会社津村 透明双氯芬酸钠的水溶液以及它的药物组合物
DE69819748T2 (de) * 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
TWI290464B (en) 2000-09-01 2007-12-01 Novartis Consumer Health Sa Treatment of burns
GB0108082D0 (en) * 2001-03-30 2001-05-23 Novartis Consumer Health Sa Topical composition

Also Published As

Publication number Publication date
PE20040321A1 (es) 2004-07-15
US20100234462A1 (en) 2010-09-16
ATE390149T1 (de) 2008-04-15
DE60319997D1 (de) 2008-05-08
AU2003264086A1 (en) 2004-03-11
WO2004017998A2 (en) 2004-03-04
BR0313701A (pt) 2005-06-28
TWI316857B (en) 2009-11-11
SI1536836T1 (sl) 2008-08-31
PT1536836E (pt) 2008-05-09
DK1536836T3 (da) 2008-07-21
EP1536836B1 (en) 2008-03-26
ES2300645T3 (es) 2008-06-16
DE60319997T2 (de) 2009-04-30
US8557870B2 (en) 2013-10-15
CA2496469C (en) 2011-07-05
AU2003264086B2 (en) 2007-01-04
US20050239894A1 (en) 2005-10-27
TW200409646A (en) 2004-06-16
US20140045942A1 (en) 2014-02-13
WO2004017998A3 (en) 2004-04-01
US7732489B2 (en) 2010-06-08
EP1536836A2 (en) 2005-06-08
US8716340B2 (en) 2014-05-06
MXPA05002077A (es) 2005-06-08
CA2496469A1 (en) 2004-03-04

Similar Documents

Publication Publication Date Title
AR041021A1 (es) Composicion topica
ES2584858T3 (es) Composiciones farmacéuticas acuosas que contienen complejos de borato-poliol
ES2703505T3 (es) Combinación de adapaleno y peróxido de benzoilo para tratar lesiones de acné
AR081364A1 (es) Composiciones farmaceuticas de pazopanib y metodos para su elaboracion
PE20010627A1 (es) Composiciones que tienen estabilidad mejorada
US20080317737A1 (en) Drug combination for the treatment of skin disorders
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
ES2161874T3 (es) Composicion oftalmica con viscosidad reducida.
AR052252A1 (es) Formulaciones topicas de nepafenac
MX9306708A (es) Composiciones de espuma de lucha contra el fuego, de un solvente polar de baja viscosidad.
CR6656A (es) Forma de dosificacion de farmacos accionada por un hidrogel
MX9305535A (es) Composiciones y concentrados germicidas a base de yodo-detergente, acuosos y estables.
AR033688A1 (es) Composicion parenteral reconstituible
CO5721018A2 (es) Pelicula detergente de dosis de unidad
CO5160288A1 (es) Composiciones liquidas que contiene una emulsion estable de un agente de particula pequena, beneficio para la piel
MX9304675A (es) Composicion farmaceutica solida en forma de dosis, que tiene un perfil de liberacion extendido, de dos etapas y proceso para su preparacion.
GT200000108A (es) Procedimiento para la obtencion de composiciones antibacteriales.
PE20110010A1 (es) Formulaciones liquidas de fenilefrina
AR041913A1 (es) Formulaciones de deposito de liberacion controlada
PE20040103A1 (es) Metodo y formas de dosificacion para incrementar la solubilidad de composiciones de farmaco para administracion controlada
BR0213226A (pt) Processo de preparação de uma composição farmacêutica sob forma de microesferas com liberação prolongada de um princìpio ativo hidrossolúvel, e, microesferas
BR0213425A (pt) Composições injetáveis para a liberação controlada de composto farmacologicamente ativo
AR066905A1 (es) Administracion intranasal de asenapina y composiciones farmaceuticas correspondientes
ECSP044974A (es) Formulación de suspensión oral estabilizada
AR033221A1 (es) Composicion farmaceutica finamente autoemulsionable

Legal Events

Date Code Title Description
FA Abandonment or withdrawal